STN- Structure Search 1-18-05

10/780,181

=> d ibib abs hitstr 1-101

L6 ANSWER 1 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1080882 CAPLUS
DOCUMENT NUMBER: 142:38062
TITLE: Preparation of protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid ester derivatives and intermediates thereof for synthesizing epothilones and derivatives
INVENTOR(S): Westermann, Juergen; Platzek, Johannes; Petrov, Orlin
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108697	A1	20041216	WO 2004-EP6057	20040605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10326195	A1	20041223	DE 2003-10326195	20030607
PRIORITY APPLN. INFO.:			DE 2003-10326195 A	20030607

GI



I



III

AB The present invention discloses methods for preparation of novel protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid ester derivs., such as I [R1, R2 = hydroxyl protecting group; R1R2 = isopropylidne; R3 = alkyl; R4 = allyl, alkenyl, alkynyl, alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, arylalkyl, etc.], and intermediates thereof for the synthesis of epothilones and epothilone derivs. Thus, 3-[(4S)-2,2-dimethyl-1,3-dioxan-4-yl]-3-methyl-butan-2-one, [obtained by the reaction of 3(S)-(3,5)-acetonedimethylketal-2,2-dimethyl-pentan-nitrile and methyllithium-lithiumbromide-complex], was treated with diallylcarbonate to afford (4S)-2,2-dimethyl-[1,3]-dioxan-4-yl-4-methyl-3-oxo-pentanoic acid allyl ester (II). II was reacted with terakistriphenylphosphinepalladium to provide (4S)-4-(2-methyl-3-oxo-hept-6-ene-2-yl)-2,2-dimethyl-[1,3]-dioxane, which was hydrogenated in presence of palladium-carbon to afford (4S)-4-(2-methyl-3-oxo-heptane-2-yl)-2,2-dimethyl-[1,3]-dioxane (III).

IT **152044-53-6DP**, Epothilone A, derivs.
RL: PNU (Preparation, unclassified); PREP (Preparation)

Double bond geometry as shown.



L6 ANSWER 54 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:120619 CAPLUS
DOCUMENT NUMBER: 140:163628
TITLE: Method for the asymmetric synthesis of epothilones and epothilone analogs
INVENTOR(S): White, James David; Sundermann, Kurt Frederick; Carter, Rich Garrett
PATENT ASSIGNEE(S): Oregon State University, USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 846,154.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004030147	A1	20040212	US 2003-354694	20030129
US 2002062030	A1	20020523	US 2001-846154	20010430
US 6596875	B2	20030722		

PRIORITY APPLN. INFO.:

US 2001-846154	A2	20010430
US 1999-118883P	P	19990205
US 2000-499596	B2	20000207

OTHER SOURCE(S): MARPAT 140:163628
GI



I

AB A method for the preparation of epothilones and analogs, such as I (R = H, alkyl, protecting group; R1 = aryl; R2 = H, alkyl; R3 = H, alkyl, R4CO, R4OCO, R4SO2; R4 = H, alkyl, aryl; X, Y = O, NH, S, CO, C) is described. Embodiments of the method provide convenient access to analogs of the epothilones, such as those having alternate stereochem. and those containing an ester, amide, thioester, or alkyne moieties in the macrocycle. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. Macrolactonization of a resulting hydroxy acid provided an intermediate diene epothilone analog which upon selective saturation of the 9,10-olefin and subsequent epoxidn. provided epothilone B. Epothilone B exhibits microtubule stabilization and has IC50 values ranging from 0.32-0.16 nM in a variety of human cancer cell lines.

IT **152044-54-7P**, Epothilone B
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of epothilones and epothilone analogs for their use as anticancer agents)

RN 152044-54-7 CAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L6 ANSWER 55 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:117139 CAPLUS
DOCUMENT NUMBER: 140:181250
TITLE: Preparation of new epothilone peptide effector conjugates for pharmaceutical use in the treatment of proliferative or angiogenesis associated disease processes
INVENTOR(S): Berger, Markus; Klar, Ulrich; Siemeister, Gerhard; Willuda, Joerg; Menrad, Andreas; Bosslet, Klaus
PATENT ASSIGNEE(S): Schering AG, Germany
SOURCE: Ger. Offen., 43 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10234975	A1	20040212	DE 2002-10234975	20020731
WO 2004012735	A2	20040212	WO 2003-EP8483	20030731
WO 2004012735	A3	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
DE 2002-10234975 A 20020731
DE 2003-10305098 A 20030207
US 2003-451673P P 20030305

OTHER SOURCE(S): MARPAT 140:181250

AB Objective: BMS 310705 is a novel water-soluble analog of epothilone B currently in phase I clin. evaluation in the treatment of malignancies such as ovarian, renal, bladder, and lung carcinoma. Using an early passage cell culture model derived from the ascites of a patient clin. refractory to platinum/paclitaxel therapy, we evaluated the pathway of caspase-mediated apoptosis. Methods: Cells were treated for 1 h and subsequently evaluated for apoptosis, survival, and caspase activity. Apoptosis was determined by fluorescent microscopy. Caspase-3, -8, and -9 activities were determined by fluorometry using target tetrapeptide substrates. Mitochondrial release of cytochrome c was determined by immunoblot anal. Results: After treatment with BMS 310705, apoptosis was confirmed in >25% of cells at 24 h. Survival was significantly lower in cells treated with 0.05 μM BMS 310705 vs. paclitaxel. Anal. revealed an increase of caspase-9 and -3 activity; no caspase -8 activity was observed Release of cytochrome c was detected at 12 h following treatment. SN-38 and topotecan failed to induce apoptosis. Conclusions: BMS 310705 induces significant apoptosis, decreases survival, and utilizes the mitochondrial-mediated pathway for apoptosis in this model.

IT **280578-49-6**, BMS 310705
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(apoptotic mitochondrial-mediated pathways for epothilone BMS 310705 antitumor action)

RN 280578-49-6 CAPLUS

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 3-[(1E)-2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 81 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:757689 CAPLUS
DOCUMENT NUMBER: 139:276755
TITLE: Preparation of epothilone derivatives for therapeutic use as anticancer agents

10/780,181

INVENTOR(S): Regueiro-Ren, Alicia; Kim, Soong-Hoon
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078411	A1	20030925	WO 2003-US7584	20030311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003191089	A1	20031009	US 2003-386072	20030311
US 6719540	B2	20040413		
EP 1483251	A1	20041208	EP 2003-714096	20030311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-363441P P 20020312
WO 2003-US7584 W 20030311

OTHER SOURCE(S): MARPAT 139:276755
GI



AB Epothilone derivs., such as I [M = bond, O, NR9, CR10R11; X = O, NH; R1-R4 = H, alkyl; R5 = H, alkyl, cyano; R6 = H, alkyl, aryl, heterocyclyl; R9-R11 = H, OH, alkyl, alkoxy, aryl, cycloalkyl, heterocyclyl], pharmaceutically acceptable salts, solvates or hydrate thereof, were prepared for use as antitumor agents. Thus, epothilone derivative II was prepared from 2,3-dehydro epothilone A, via silylation of hydroxyl group, potassium cyanide addition, followed by deprotection. The prepared epothilone derivs. were assayed in vitro for their effect on tubulin polymerization and for cytotoxicity against HCT-116 human colon carcinoma cells. Therapeutic compns. containing I or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases are also claimed.

IT **476623-89-9P 476623-90-2P 476623-91-3P 476623-92-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 98 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:494858 CAPLUS
DOCUMENT NUMBER: 139:159461

TITLE: The high-resolution solution structure of epothilone a bound to tubulin: An understanding of the structure-activity relationships for a powerful class of antitumor agents

AUTHOR(S): Carlomagno, Teresa; Blommers, Marcel J. J.; Meiler, Jens; Jahnke, Wolfgang; Schupp, Thomas; Petersen, Frank; Schinzer, Dieter; Altmann, Karl-Heinz; Griesinger, Christian
CORPORATE SOURCE: Max-Planck-Institut fuer Biophysikalische Chemie Am Fassberg 11, Goettingen, 37077, Germany

SOURCE: Angewandte Chemie, International Edition (2003), 42(22), 2511-2515
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The tubulin-bound structure of epothilone A (shown in green) differs substantially form its free conformation (determined by x-ray crystallog., shown in gray). The new structural data correlate well with results from chemical modification expts., giving a consistent picture of the functionally important regions of epothilone.

IT **152044-53-6**, Epothilone A **152044-54-7**, Epothilone B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high-resolution solution structure of epothilone a bound to tubulin with an understanding of structure-activity relationships for a powerful class of antitumor agents)

RN 152044-53-6 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 99 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:482921 CAPLUS

DOCUMENT NUMBER: 140:35422
TITLE: Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
AUTHOR(S): Agrawal, Manish; Edgerly, Maureen; Fojo, Tito; Kotz, Herb
CORPORATE SOURCE: National Cancer Institute Building 10/12C103, Center for Cancer Research, Bethesda, MD, 20892, USA
SOURCE: Gynecologic Oncology (2003), 90(1), 96-99
CODEN: GYNOA3; ISSN: 0090-8258
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype. There are limited therapeutic options for women with advanced cervical adenocarcinoma. Only a few chemotherapy agents have demonstrated activity in this disease. This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix. We present two women with recurrent cervical adenocarcinoma with metastases to the lung. Both women were treated previously with paclitaxel and were enrolled in a phase I study with BMS-247550. Both women had partial responses to BMS-247550 with a decrease in tumor size and CA-125 levels. The demonstration of a response to BMS-247550, especially after addnl. chemotherapy had been administered, is encouraging, albeit preliminary. The ultimate role of BMS-247550 and multiagent chemotherapy in the treatment of adenocarcinoma of the cervix should be further investigated.
IT **152044-54-7D**, Epothilone B, analog
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilone B analog BMS-247550 in treatment of recurrent cervical adenocarcinoma)
RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 100 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:472384 CAPLUS
DOCUMENT NUMBER: 139:30796
TITLE: Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
INVENTOR(S): Rothermel, John David; Rubin, Eric Howard
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003049734	A1	20030619	WO 2002-EP14162		20021212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR					
EP 1463504	A1	20041006	EP 2002-790487		20021212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002014917	A	20041130	BR 2002-14917		20021212
PRIORITY APPLN. INFO.:			US 2001-342167P	P	20011213
			US 2002-415990P	P	20021004
			WO 2002-EP14162	W	20021212

OTHER SOURCE(S): MARPAT 139:30796

AB Use of a compound of formula (I) wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is Me, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, alone or in combination with at least one compound selected from the group consisting of somatostatin or a synthetic derivative thereof, interferon- 5-fluorouracil, doxorubicin, cyclophosphamide, streptozotocin and a standard anti-diarrheal, for the preparation of a medicament for the treatment of carcinoid syndrome or at least one neuroendocrine tumor. A method is disclosed for the treatment of a warm-blooded animal, having carcinoid syndrome and/or at least one neuroendocrine tumor. A combination comprising a compound formula I as defined above and at least one compound selected from the group provided above; and to a com. package comprising said combination.

IT **152044-54-7**, Epothilone B **152044-54-7D**, Epothilone B, derivative
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising epothilones and their use for treatment of carcinoid syndrome)

RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 101 OF 453 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:454610 CAPLUS
DOCUMENT NUMBER: 139:30789
TITLE: Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
INVENTOR(S): Atadja, Peter Wisdom; Hoving, Sjouke; Towbin, Harry; Walker, Heather Brownlee; Wartmann, Markus; Yeleswarapu, Lakshmi
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma Gmbh
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048774	A1	20030612	WO 2002-EP13873	20021206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
EP 1456664	A1	20040915	EP 2002-795117	20021206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-338231P P 20011207
WO 2002-EP13873 W 20021206

AB The invention relates to a novel method for evaluating the antiproliferative activity of protein deacetylase inhibiting compds. and microtubule interacting agents, as well as a method for screening for compds. that inhibit cell growth or growth of tumors. The invention addnl. provides a method for monitoring the progress of treatment against cellular growth or the growth of tumors.

IT **152044-54-7**, Epothilone B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of alpha-tubulin acetylation levels as biomarker for protein deacetylase inhibitors)

RN 152044-54-7 CAPLUS
CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:04:19 ON 18 JAN 2005)

FILE 'REGISTRY' ENTERED AT 11:04:30 ON 18 JAN 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 STRUCTURE UPLOADED
L4 21 S L3
L5 468 S L3 FULL

FILE 'CAPLUS' ENTERED AT 11:07:23 ON 18 JAN 2005
L6 453 S L5

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 C,B

Structure attributes must be viewed using STN Express query preparation.

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

PALM INTRANET

Day : Tuesday
Date: 1/18/2005
Time: 10:57:54

Inventor Name Search Result

Your Search was:

Last Name = HOEFLE
First Name = GERHARD

Application#	Patent#	Status	Date Filed	Title	Inventor Name 19
60191975	Not Issued	159	03/24/2000	PREPARATION OF EPOTHILONE INTERMEDIATES	HOEFLE, GERHARD
60167399	Not Issued	159	11/24/1999	FUNGICIDAL MELITHIAZOLE DERIVATIVES	HOEFLE , GERHARD
60148482	Not Issued	159	08/12/1999	FUNGICIDAL HETEROARYL HEPTA-2,6- DIENOC ACID DERIVATIVES	HOEFLE , GERHARD
10988328	Not Issued	020	11/12/2004	EPOTHILONES C, D, E AND F, PREPARATION AND COMPOSITIONS	HOEFLE, GERHARD
10780181	Not Issued	030	02/17/2004	EPOTHILONE DERIVATIVES, A PROCESS FOR THEIR PRODUCTION THEREOF AND THEIR USE	HOEFLE, GERHARD
10602770	6831076	150	06/25/2003	EPOTHILONS C AND D, PREPARATION AND COMPOSITIONS	HOEFLE, GERHARD
10468919	Not Issued	030	12/12/2003	DEGRADATION OF EPOTHILONES	HOEFLE, GERHARD
10457098	Not Issued	030	06/06/2003	EPOTHILONE SIDE COMPONENTS	HOEFLE, GERHARD
10381176	Not Issued	092	08/18/2003	TRIAZOLO-EPOTHILONES	HOEFLE, GERHARD
09836134	6613912	150	04/16/2001	EPOTHILONS C AND D, PREPARATION AND COMPOSITIONS	HOEFLE, GERHARD
09719932	6624310	150	03/21/2001	EPOTHILONE MINOR CONSTITUENTS	HOEFLE, GERHARD
09674877	Not Issued	164	01/02/2001	EPOTHILONE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, AND	HOEFLE, GERHARD

				THEIR USE	
09506481	6262094	150	02/17/2000	C-21 MODIFIED EPOTHILONES	HOEFLE, GERHARD
09449143	Not Issued	161	11/24/1999	FUNGICIDAL MELITHIAZOLE DERIVATIVES	HOEFLE , GERHARD
09416195	Not Issued	161	10/11/1999	DNA SEQUENCES FOR ENZYMATIC SYNTHESIS OF POLYKETIDE OR HETEROPOLYKETIDE COMPOUNDS	HOEFLE, GERHARD
09402855	6197802	150	01/19/2000	FUNGICIDAL MELITHIAZOLE DERIVATIVES	HOEFLE , GERHARD
09372857	Not Issued	164	08/12/1999	FUNGICIDAL HETEROARYL HEPTA-2,6-DIENOIC ACID DERIVATIVES	HOEFLE , GERHARD
09313524	Not Issued	172	05/17/1999	EPOTHILONES C, D, E AND F, PREPARATION AND COMPOSITIONS	HOEFLE , GERHARD
09077055	6288237	150	08/03/1998	EPOTHILONS C AND D, PREPARATION AND COMPOSITIONS	HOEFLE , GERHARD

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Hoefle **First Name** Gerhard

Search

To go back use Back button on your browser toolbar.